Surrogate Virus Neutralization Test (sVNT) to determine salivary neutralizing antibody inhibition of ACE2 and SARS-CoV-2 Spike RBD complex - Takeaways - MDSpire

Surrogate Virus Neutralization Test (sVNT) to determine salivary neutralizing antibody inhibition of ACE2 and SARS-CoV-2 Spike RBD complex

  • By

  • Forsman, David

  • Smith, Abigail Rose

  • Pratt, Alex

  • Comerford, Paige

  • Sparano, Fiona

  • Peng, Congyue

  • Dean, Delphine

  • May 21, 2026

  • 0 min

Share

  • 1

    SARS-CoV-2 enters human cells via the hACE-2 and viral spike protein complex, making neutralizing antibodies crucial for blocking infection.

  • 2

    The study utilized a laboratory-developed surrogate virus neutralization test (sVNT) to evaluate salivary antibody activity against SARS-CoV-2.

  • 3

    Saliva samples were collected from donors who received two doses of the Pfizer vaccine and a booster shot, averaging 36.6 weeks apart.

  • 4

    Vaccine-elicited saliva antibodies effectively blocked hACE-2 binding to the spike RBD of the reference strain but failed against the Omicron variant.

  • 5

    The findings suggest that the sVNT can be adapted for assessing immune protection against various pathogens beyond SARS-CoV-2.

Original Source(s)

Surrogate Virus Neutralization Test (sVNT) to determine salivary neutralizing antibody inhibition of ACE2 and SARS-CoV-2 Spike RBD complex

  • by Forsman, David , Smith, Abigail Rose, Pratt, Alex , Comerford, Paige , Sparano, Fiona , Peng, Congyue , Dean, Delphine

  • May 21, 2026

Related Content

Adjuvant-driven epitope hierarchy correlates with the protective efficacy of FimA vaccine against Klebsiella pneumoniae

CD4 T cell phenotype after AS01-adjuvanted immunization is shaped by prior antigen or pathogen exposure

Rare or Unverified Outcomes Shape Vaccine Safety and Gender Care Debates — The Monitor